Palvella Therapeutics, Inc. (PVLA) NASDAQ

Currency In USD

Palvella Therapeutics, Inc.

Address

125 Strafford Avenue

Wayne, PA 19087

United States of America (the)

Phone

484 253 1461

Website

https://palvellatx.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

January 02, 2015

Key Executives

Name	Title	Pay	Year Born
Wesley H. Kaupinen	Founder, President, Chief Executive Officer & Director	935,018	N/A
Jeffrey Martini	Chief Scientific Officer	530,435	1978
Matthew E. Korenberg	CFO, Corporate Secretary & Treasurer	665,420	1975
Kathleen Goin	Chief Operating Officer	673,820	1971
Ashley Kline	Chief Commercial Officer	0	1981
Bohan Wei	Vice President of Corporate Development & New Product Planning	0	N/A
Emily Cook	Senior Vice President of Clinical Operations	0	N/A
Jennifer McDonough	Senior Vice President of Market Access & Patient Services	0	N/A
Sarah Foster	Senior Vice President of Human Resources	0	N/A
Vimal Patel	Senior VP of Medical Affairs	0	N/A
Jason Burdette	SVP of CMC & Technical Operations	0	N/A
Kent Taylor	Senior Vice President of Sales	0	N/A
David W. Osborne	Chief Innovation Officer	0	1961

Description

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.